Compare Hyatt Hotels Corporation (H) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Twist Bioscience Corp — how do they compare? Hyatt Hotels Corporation trades at $191.25 (market cap $17.85B), while Twist Bioscience Corp trades at $93.87 (market cap $5.45B). The key difference: Hyatt Hotels Corporation is far larger — about 3.3× Twist Bioscience Corp's market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| H | TWST | |
|---|---|---|
Market Cap | $17.85B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $102.88 |
52-Week Low | $135.01 | $24.16 |
Enterprise Value | $21.69B | $5.37B |
Dividend Yield | 0.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $189.75, down 0.47% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $198. Recent earnings show mixed results, with Q2 2026 expected at $0.89 EPS. The company maintains strategic expansions, including new hotel openings and partnerships, while facing profitability challenges with a negative net income margin of -0.48% in 2025.
The stock presents a moderate buy opportunity with analyst support, but risks include declining cash flows and elevated debt. Upside hinges on execution of growth initiatives and improved earnings, while macroeconomic pressures on travel demand pose headwinds. Investors should weigh the 37.5% buy rating against fundamental weaknesses.
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
